**Emcure Pharmaceuticals to Expand Gynaecology and Dermatology Portfolio by FY26**
Pune-based Emcure Pharmaceuticals is set to enhance its gynaecology and dermatology product offerings in the Indian market by FY26, as announced by the company’s CEO and Managing Director, Satish Mehta, during a recent earnings call. The firm has already made strides in women’s health by launching a range of products targeting menopause and PCOS in FY25. Mehta indicated that the company is actively working to strengthen its presence in the gynaecology sector with additional product launches planned for FY26.
Following its stock market debut in July 2024, Emcure reported a profit after tax of ₹197 crore for Q4FY25, marking a 63% increase year-on-year. Revenue also saw a significant rise of 19.5% year-on-year, reaching ₹2,116 crore, driven by a robust 24.8% growth in its domestic business and a 15.6% increase in international markets. Mehta highlighted that the domestic business’s strong performance was primarily fueled by advancements in women’s health, cardiology, and dermatology.
The company’s international business, which encompasses markets in Canada, Europe, and the rest of the world, experienced a 15.6% growth. Mehta emphasized that successful execution and a focus on improving profitability will be crucial for the company’s outlook in FY26, with a targeted revenue growth of 13-14% and an anticipated margin improvement of approximately 150 basis points.
In addition to its women’s health initiatives, Emcure has sharpened its focus on dermatology through the establishment of its subsidiary, Emcutix Biopharmaceuticals, which has introduced two cosmetic skincare products: a skin-tightening treatment and a urea-based moisturizer. Mehta noted that the company has a promising pipeline of products set to enhance its portfolio over the next year, alongside numerous collaboration opportunities in the dermatology sector.
Emcure has also integrated Sanofi’s cardiology portfolio into its operations for the Indian market. Mehta expressed satisfaction with the completion of the restructuring of the cardio-diabetic business, which is expected to drive future growth. Furthermore, the company is preparing for the launch of the weight-loss drug semaglutide in India next year.
Looking ahead, Emcure plans to concentrate on complex injectables, biosimilars, and innovative drug delivery methods for existing molecules, with a particular emphasis on central nervous system (CNS) treatments and antibody drug conjugates (ADCs).
**FAQ**
**What are Emcure Pharmaceuticals’ plans for FY26?**
Emcure Pharmaceuticals aims to expand its gynaecology and dermatology product portfolio in the Indian market, with additional launches planned to enhance its offerings in women’s health and skincare.